Sonia T. Oskouei, PharmD: Biosimilars and Misinformation

Sonia T. Oskouei, PharmD, vice president of innovation and solution development at Premier Inc, discusses biosimilars and misinformation.
August 26, 2019



Transcript

So, it is hard to manage all of the information that’s out there. Understandably, there’s a lot of different data sources and sites where you can get information, so to manage it all alone is a challenge. But there’s different information out there that talks about aspects of biosimilars, from interchangeability to extrapolation. When it’s out there, it could cause a misunderstanding about biosimilars, whether it’s intentional or not. So that’s, again, the need for education from a patient and provider level to help clarify any of those aspects with biosimilars.

x-button

Click here to view Biosimilars CME Activities

Click here to view Biosimilars PTCE Activities

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2019 Intellisphere, LLC. All Rights Reserved.